382 completed, 69 unknown, 40 terminated, 32 withdrawn. 131 Not applicable, 123 Phase 4, 122 Phase 2, 87 Phase 3, 80 Phase 1.
Follow Insulin: new trials by email Literature Review of Insulin trials Research Report on Insulin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dose Response Study of Transdermal Human Insulin in Patients Human Insulin, Finger-actuated, Metered Pump Sprayer - Glucose, High Blood | Phase 2 / Phase 3 | Not yet recruiting | Transdermal Delivery Solutions Corp | 30 | 2027-09-02 | 2026-05-26 |
| Human Models of Selective Insulin Resistance: Pancreatic Clamp Insulin human, Octreotide Acetate, Glucagon - Insulin Resistance, Hyperinsulinemia | Phase 1 | Not yet recruiting | Columbia University | 36 | 2027-01-01 | 2026-02-06 |
| Peripheral Vascular Effects of Insulin in Obesity human insulin - Obesity (BMI>30), Insulin Resistance | Early Phase 1 | Not yet recruiting | University of Missouri-Columbia | 64 | 2026-12-01 | 2026-10-15 |
| Interplay of Central and Peripheral Vascular Effects of Insulin in Obesity human insulin - Obesity (BMI>30), Insulin Resistance | Early Phase 1 | Not yet recruiting | University of Missouri-Columbia | 64 | 2026-12-01 | 2026-10-15 |
| Restoring Vascular and Insulin Function To Augment Anti-Amyloid Therapy in Alzheimer's Disease Empagliflozin, Insulin, Insulin Placebo - Alzheimer Disease | Phase 2 | Not yet recruiting | Wake Forest University Health Sciences | 30 | 2026-11-01 | 2026-09-30 |
| Topical Insulin for Glaucoma (TING2) EYED-002 Low Dose (721 U/mL topical insulin), EYED-002 High Dose (1442 U/mL topical insulin), EYED-002 (highest tolerated dose, 12-month) - Open Angle Glaucoma, Primary Open Angle Glaucoma | Phase 1 / Phase 2 | Enrolling by invitation | Stanford University | 90 | 2026-09-10 | 2026-10-13 |
| Local Application of Insulin Versus Hyaluronic Acid in Stage III Periodontitis Insulin, Hyaluronic acid gel, mechanical debridement - Treatment of Stage III Periodontitis, Local Application of Insulin in Pockets | Early Phase 1 | Recruiting | Doaa Atta Aid | 45 | 2026-07-24 | 2026-08-04 |
| Sleep Loss and Circadian Misalignment - Mechanisms of Insulin Resistance Metyrapone And Hydrocortisone, Dextrose, insulin - Shift Work Schedule, Circadian Rhythm | Phase 4 | Recruiting | Washington State University | 48 | 2026-07-16 | 2026-09-18 |
| Intranasal Insulin for Postoperative Delirium in Older Patients With T2DM Insulin, human, Intranasal Normal Saline (Placebo) - Postoperative Delirium (POD) | Not applicable | Not yet recruiting | Weidong Mi | 210 | 2026-07-01 | 2026-07-22 |
| Bioavailability, Biopotency and Food Effect Study of SCD0503 Compared to Subcutaneous Regular Human Insulin oral insulin, Placebo A, subcutaneous insulin - Diabetes Mellitus, Type 1 | Phase 1 | Recruiting | Sam Chun Dang Pharm. Co. Ltd. | 16 | 2026-05-29 | 2026-06-09 |
| Effects of Cofrogliptin on Beta-Cell Function in LADA Patients Cofrogliptin, Vitamin D3, Metformin - Latent Autoimmune Diabetes in Adults (LADA) | Not applicable | Not yet recruiting | Second Xiangya Hospital of Central South University | 84 | 2026-05-15 | 2026-05-08 |
| Open-Label Study of Dimethyl Fumarate in Adults With Type 1 Diabetes Dimethyl Fumarate Enteric-coated Capsules, Insulin - Type 1 Diabetes Mellitus | Phase 2 / Phase 3 | Recruiting | Nanjing Medical University | 96 | 2026-04-27 | 2026-07-21 |
| Intranasal Platelet-Rich Plasma With or Without Topical Insulin for Post-Inflammatory Anosmia Intranasal PRP Plus Topical Insulin, Intranasal PRP Plus Saline (Placebo) - Anosmia, Inflammatory Anosmia | Not applicable | Not yet recruiting | Amin Javer | 20 | 2026-03-30 | 2026-02-03 |
| Insulin Intratympanic Application Insulin (Humulin), foam - Tympanic Membrane Perforation | Early Phase 1 | Completed | Deraya University | 50 | 2026-03-20 | 2026-09-04 |
| Permissive Versus Strict Intrapartum Glucose Management in Type 1 Diabetes (PRISM-T1D) Insulin, DEXCOM Continuous Glucose Monitor - Pregnancy, High Risk, Type 1 Diabetes | Phase 4 | Recruiting | Ohio State University | 44 | 2026-02-25 | 2026-04-29 |
| Safety and Feasibility of Intranasal Insulin in Patients With Spinal Cord Injury Regular Insulin, 0.9 % Normal Saline - Spinal Cord Injury | Phase 1 | Recruiting | HealthPartners Institute | 12 | 2026-02-20 | 2026-09-15 |
| INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes Technosphere Insulin, Basal insulin - Type 1 Diabetes Mellitus | Phase 2 | Recruiting | Mannkind Corporation | 100 | 2026-02-04 | 2026-08-13 |
| Adding Evolocumab to Conventional Lipid-lowering Therapy for Hypertriglyceridemia Induced Acute Pancreatitis Evolocumab 140 MG/ML [Repatha], Conventional lipid-lowering therapy - Hypertriglyceridemia Induced Acute Pancreatitis | Not applicable | Recruiting | General Hospital of Shenyang Military Region | 60 | 2026-01-02 | 2026-09-25 |
| A Study of GS3-007a for Oral Suspension in the Diagnosis of Adult Growth Hormone Deficiency (AGHD) GS3-007a dry suspension, Insulin - Adult Growth Hormone Deficiency (AGHD) | Phase 2 | Terminated | Changchun GeneScience Pharmaceutical Co., Ltd. | 120 | 2025-12-19 | 2026-05-22 |
| A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus. ORMD-0801 8 mg, Placebo capsule, ORMD-0801 16 mg - Type 2 Diabetes Mellitus | Phase 3 | Not yet recruiting | Oramed, Ltd. | 300 | 2025-12-15 | 2025-08-03 |
Showing 20 of 572. Sign in to see all of them.
Insulin Resistance (159) · Diabetes Mellitus, Type 2 (154) · Diabetes Mellitus (126) · Diabetes Mellitus, Type 1 (117) · Hyperglycemia (47) · Hypoglycemia (35) · Diabetes, Gestational (31) · Obesity (25) · Cognitive Dysfunction (11) · Hyperinsulinism (10) · Alzheimer Disease (9) · Diabetic Ketoacidosis (7) · Non-alcoholic Fatty Liver Disease (7) · Dyslipidemias (6) · Glucose Metabolism Disorders (6)
Novo Nordisk A/S (22) · Oramed, Ltd. (13) · Institut de Recherches Cliniques de Montreal (12) · Mannkind Corporation (11) · Merck Sharp & Dohme LLC (11) · Emory University (9) · Sanofi (8) · AstraZeneca (7) · Eli Lilly and Company (7) · University of Aarhus (7) · Biodel (6) · Cairo University (6) · Halozyme Therapeutics (6) · HealthPartners Institute (6) · Mayo Clinic (6)
United States (229) · Germany (47) · Canada (44) · China (37) · France (25) · United Kingdom (25) · Egypt (24) · Denmark (22) · Italy (18) · India (13) · Israel (13) · Brazil (12) · Poland (12) · Spain (12) · Japan (11)
Suzanne Craft, PhD (7) · Guillermo Umpierrez, MD (6) · Joel M Neutel, M. D. (5) · Betty Tuller, PhD (4) · Miriam Kidron, PhD (4) · Joshua R Cook, MD, PhD (3) · Kazuoki Kondo, MD (3) · Leah R Hanson, PhD (3)
PMID 37526194, PMID 11889147, PMID 17513708, PMID 18184958, PMID 19366972, PMID 19636533, PMID 19898642, PMID 21228246, PMID 23435159, PMID 32803882, PMID 33367811, PMID 34091488, PMID 36656551, PMID 10445833, PMID 10546015, PMID 10711923, PMID 10735458, PMID 10950834, PMID 11105967, PMID 11162047, PMID 11219223, PMID 11347758, PMID 11512567, PMID 11794168, PMID 11943004, PMID 12037147, PMID 12076560, PMID 12502678, PMID 12630816, PMID 12719395, PMID 12933380, PMID 14583175, PMID 15273558, PMID 15575341, PMID 15798081, PMID 15855569, PMID 15951574, PMID 16030064, PMID 16043738, PMID 16075050, PMID 16365098, PMID 16464955, PMID 16504835, PMID 16607131, PMID 16614412, PMID 16614616, PMID 16627388, PMID 16685053, PMID 16705054, PMID 16738506
2015 (3), P30DK063608 (3), 2005 (2), 2017 (2), 2018 (2), 2004 (1), 2008 (1), 2009 (1), 2014 (1), 2016 (1), 2019 (1), 2023 (1), K12DK133995 (1), K23DK109284 (1), K23HD092893 (1)